ArticleBMC nephrology2026
A case report of concomitant anti-glomerular basement membrane disease, IgA nephropathy, and membranous nephropathy.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe coexistence of anti-glomerular basement membrane (anti-GBM) disease, IgA nephropathy (IgAN), and membranous nephropathy (MN) represents an exceptionally rare glomerular pathology triad, with only one previously documented case. This study explores the underlying mechanisms linking these distinct entities and reports a novel case associated with persistent elevation of serum amylase and lipase, thereby expanding the clinical spectrum of this complex disease combination.
methodsA 51-year-old woman presenting with recurrent macroscopic hematuria and rapidly progressive renal dysfunction was diagnosed with simultaneous triple glomerulopathy based on positive anti-GBM antibodies and renal biopsy findings. An integrated therapeutic regimen was administered, including high-dose methylprednisolone pulse therapy, cyclophosphamide, intensive plasma exchange (PE), and hemodialysis.
resultsTreatment led to undetectable anti-GBM antibody titers within two months, successful discontinuation of hemodialysis by the third month, and complete resolution of hematuria. By the ten-month follow-up, proteinuria and serum creatinine levels significantly decreased, renal function stabilized with normal urine output, and no significant adverse events were observed.
conclusionsThis case demonstrates the pathological coexistence of triple glomerulopathy. Although clinical improvement was observed after a combined regimen of early PE and immunosuppression, causality cannot be inferred from a single case. These findings provide hypothesis-generating insights for the management of similar complex cases and highlight the need for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.